This Week in Virology TWiV 1265: mRNA vaccines make cancer treatment great again
Oct 26, 2025
Discover how SARS-CoV-2 mRNA vaccines may enhance cancer treatment outcomes and prolong survival for patients receiving immunotherapy. The discussion delves into the mechanism of immune checkpoint inhibitors and the promising findings from recent studies. Learn how mRNA vaccines can reactivate cold tumors, offering new hope for treatment strategies. Additionally, explore how antigenic cartography could shape future influenza vaccines and pandemic preparedness while featuring unique listener anecdotes and valuable health insights.
AI Snips
Chapters
Transcript
Episode notes
Systemic Innate Activation Recruits Tumor‑Killing T Cells
- mRNA-LNPs activate myeloid antigen-presenting cells and LY6C+ populations, increasing tumor antigen presentation and CD8 T cell expansion.
- This systemic innate activation drives tumor infiltration and PD-L1 upregulation, creating a window for checkpoint blockade.
Vaccination Can Raise Tumor PD‑L1 And Alter Treatment Choice
- Patients vaccinated within 100 days before tumor biopsy had higher tumor PD-L1 proportion scores, often moving some above the 50% treatment threshold.
- That shift can change treatment decisions by making more patients eligible for ICI.
Warming Cold Tumors Restores ICI Sensitivity
- In patients with baseline TPS <1% (immunologically cold tumors), mRNA vaccination near ICI restored survival to levels seen in TPS >1% patients.
- Thus mRNA-LNPs can 'warm up' cold tumors and sensitize them to checkpoint blockade.